EGFR and central nervous system cancer: Mice were treated with 2nd generation short spacer EGFR806-CAR, Erbitux-CAR (positive control which is expected to be activated by both glioma and EGFR-expressing teratoma), and CD19-directed CAR T cells (CD19-CAR, negative control that is only activated by the CD19-overexpressing glioma, but not the teratoma).